Novartis finds its next mass-market ophthalmology drug candidate at a small virtual biotech with a global view
Like me, you may never have heard about Lubris BioPharma before today. But Novartis has. And that is by far more important.
Today the pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
